ProCE Banner Activity

Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial

Slideset Download
Conference Coverage
Abatacept achieved an ORR of 49% and sustained reduction in prednisone dosing over time in patients with steroid-refractory chronic GVHD.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation